Dr. Lukas Manka: Kongressbeiträge

  1. 2011 at AUA Washington DC.,USA: Real time tissue imaging by elastography in patients with negative biopsy and rising PSA (Poster)

  2. 2013 at Global congress on Prostate cancer  Marseille, France: Quality-of-Life (QoL) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with Cabazitaxel – interim analysis of a prospective non-interventional trial (QoLiTime) (Poster)

  3. 2013 Nordkongress, Hamburg, Germany: Bei Patienten mit einer Indikation zur Prostat-Biopsie zeigt die 3-Tesla Magnetresonanz-Spektroskopie ohne rektale Spule einen hohen negativen predikativen Wert In patients indicated for prostate biopsy, the 3-tesla magnetic resonance spectroscopy without rectal coil is associated with high negative predictive value (Poster)

  4. 2013 Nordkongress, Hamburg, Germany: Die Validität der PSA-Dichte-Messung als diagnostisches Hilfsmittel beim Prostata-Karzinom (The validity of using prostate specific antigen density as a diagnostic tool for prostate cancer) (Presentation)

  5. 2013 Nordkongress, Hamburg, Germany: Magnetresonanz-Spektroskopie zeigt bei Patienten vor radikaler Prostatektomie hohe Spezifität (In patients who underwent radical prostatectomy, pre-operative proton magnetic resonance spectroscopy is associated with high specificity (Presentation)

  6. 2013 Nordkongress, Hamburg, Germany: Is use of statin associated with better histopathologic parameters in men with biopsy proven cancer? A retrospective matched controlled anaylsis (Poster)

  7. 2013 SWDGU Baden-Baden, Germany: Unterschiede in der neoadjuvante Hormonentzugstherapie zur Volumenreduktion und LUTS-Entlastung beim Vergleich von Degarelix vs. Goserelin + Bicalutamid (Presentation)

  8. 2013 DGU (German Congress of Urology) Dresden, Germany: In Patients Indicated for Prostate Biopsy, the 3-Tesla Magnetic Resonance Spectroscopy without Rectal Coil is Associated with High Negative Predictive Value (Poster)

  9. 2013 DGU (German Congress of Urology) Dresden, Germany: Prospektive Evaluation der Real Time Elastographie bei Patienten mit negativer Biopsie und steigendem PSA-Werten (Presentation)

  10. 2013 DGU (German Congress of Urology): Therapie des kastrationsresistenten Prostatakarzinoms mit Abirateron: Update der Ergebnisse aus dem deutschen Härtefallprogramm (Co-Author)

  11. 2013 at SIU-Vancouver, Canada: Is use of statin associated with better histopathologic parameters in men with biopsy proven cancer? A retrospective matched controlled anaylsis (Poster)

  12. 2013 at SIU-Vancouver, Canada: Prospective evaluation of real time tissue imaging by elastography in patients with previous negative biopsy and rising PSA (moderated Poster)

  13. 2013 at SIU-Vancouver, Canada: In patients who underwent radical prostatectomy, the pre-operative 3-tesla magnetic resonance spectroscopy without rectal coil is associated with high specificity (moderated Poster)

  14. 2013 at the Brasilan Internatinal Congress of Urology, Natal, Brazil;Is use of statin associated with better histopathologic parameters in men with biopsy proven cancer? A retrospective matched controlled anaylsis (Poster)

  15. 2013 at the Brasilan Internatinal Congress of Urology, Natal, Brazil;Prospective evaluation of real time tissue imaging by elastography in patients with previous negative biopsy and rising PSA (Poster)
  16. 2013 at the Brasilan Internatinal Congress of Urology, Natal, Brazil; In patients who underwent radical prostatectomy, the pre-operative 3-tesla magnetic resonance spectroscopy without rectal coil is associated with high specificity (Poster)

  17. 2014 at the Annual Meeting of the American Urological Association (AUA),Orlando, USA: Prospective evaluation of real time tissue imaging by elastography in patients with previous negative biopsy and rising PSA (Poster)

  18. 2014 at the Annual Meeting of the American Urological Association (AUA), Orlando, USA:FUTURE RISK FOR INTERMEDIATE OR HIGH RISK PROSTATE CANCER IN MEN WITH BASELINE PSA OF 1-3NG/ML AND LOW FREE-TO-TOTAL PSA-RATIO IN A PROSPECTIVE POPULATION- BASED SCREENING TRIAL (ERSPC AARAU) (co-author)

  19. 2014 at the Annual Meeting of the American Urological Association (AUA),Orlando,USA THE IMPACT OF FAMILY HISTORY ON PROSTATE CANCER INCIDENCE AND -AGGRESSIVENESS IN A POPULATION-BASED SCREENING TRIAL (ERSPC AARAU) (co author)

  20. 2014 at German Assosisation of Radiooncology (DGRO), Düsseldorf, Germany: Stärkere kurzfristige Linderung der Symptome der unteren Harnwege in allen Stadien des Prostatakarzinoms bei Patienten, die mit Degarelix behandelt wurden (im Vergleich zu Goserelin/Bicalutamid): Ergebnisse einer Metaanalyse

  21. 2014 DGU (German Congress of Urology), Düsseldorf, Germany: Bedeutung der Familienanamnese bezüglich Prostatakarzinom-Inzidenz und –Aggressivität im Populations-basierten Screening Setting (ERSPC Aarau)  (Co-Author)

  22. 2014 DGU (German Congress of Urology), Düsseldorf, Germany: Einfluss von Metformin auf die Prostatakarzinom-Inzidenz und Mortalität im Population-basierten Screening (ERSPC Aarau) (Co-Author)

  23. 2014 DGU (German Congress of Urology), Düsseldorf, Germany: Prospektives Risiko für intermediate und high risk Prostatakarzinom bei Männern mit baseline PSA 1-3ng/ml und tiefer PSA-Ratio im Populations-basierten Screening (ERSPC Aarau) (Co-Author)